Skip to main content
Top
Published in: Archives of Dermatological Research 2/2018

01-03-2018 | Concise Communication

Matrix metalloproteinase-2 and -9 activity levels increase in cutaneous lupus erythematosus lesions and correlate with disease severity

Authors: Goksen Ertugrul, Didem Keles, Gulgun Oktay, Sebnem Aktan

Published in: Archives of Dermatological Research | Issue 2/2018

Login to get access

Abstract

Lupus erythematosus is a chronic autoimmune disease characterized by remissions and exacerbations. Accumulated evidence indicated that matrix metalloproteinases (MMPs) are upregulated in inflammatory cells of cutaneous lupus erythematosus (CLE); however, the activity levels of these proteases have remained uncharacterized. To elucidate the significance of MMP-2, MMP-9, and TIMP-1 in CLE pathogenesis, gelatin zymography was used to investigate pro and active levels of MMP-2 and MMP-9 in lesional and perilesional skin biopsies obtained from twenty-two CLE patients. TIMP-1 protein levels were detected by ELISA in the biopsy specimens. The correlation between biochemical parameters and clinical characteristics of the disease was also evaluated. Significantly higher levels of active MMP-2, active MMP-9, proMMP-9, active/proMMP-2, and TIMP-1 were detected in lesional skin samples. Besides, the active/proMMP-9 was elevated in female and smoking patients. Active MMP-9 levels and active/proMMP-9 were also increased in elderly patients. Active MMP-9 levels were lower in patients who had smaller total damage score. Consistently, active/proMMP-9 and active/proMMP-2 were positively correlated with CLASI. Interestingly, in hydroxychloroquine or topical corticosteroid-treated patients, MMP-2/-9 activity levels were found to be higher compared to untreated patients. These findings suggest that increased MMP-2 and MMP-9 activities may contribute to the pathogenesis of CLE and cutaneous disease severity.
Literature
3.
go back to reference Axisa B, Loftus IM, Naylor AR, Goodall S, Jones L, Bell PR, Thompson MM (2002) Prospective, randomized, double-blind trial investigating the effect of doxycycline on matrix metalloproteinase expression within atherosclerotic carotid plaques. Stroke 33:2858–2864CrossRefPubMed Axisa B, Loftus IM, Naylor AR, Goodall S, Jones L, Bell PR, Thompson MM (2002) Prospective, randomized, double-blind trial investigating the effect of doxycycline on matrix metalloproteinase expression within atherosclerotic carotid plaques. Stroke 33:2858–2864CrossRefPubMed
6.
go back to reference Djamgoz MBA, Mycielska M, Madeja Z, Fraser SP, Korohoda W (2001) Directional movement of rat prostate cancer cells in direct-current electric field: involvement of voltage-gated Na+ channel activity. J Cell Sci 114:2697–2705PubMed Djamgoz MBA, Mycielska M, Madeja Z, Fraser SP, Korohoda W (2001) Directional movement of rat prostate cancer cells in direct-current electric field: involvement of voltage-gated Na+ channel activity. J Cell Sci 114:2697–2705PubMed
7.
go back to reference Faber-Elmann A, Eilat E, Zinger H, Mozes E (2002) A peptide based on an anti-DNA autoantibody downregulates matrix metalloproteinases in murine models of lupus. Clin Immunol 105:223–232CrossRefPubMed Faber-Elmann A, Eilat E, Zinger H, Mozes E (2002) A peptide based on an anti-DNA autoantibody downregulates matrix metalloproteinases in murine models of lupus. Clin Immunol 105:223–232CrossRefPubMed
8.
go back to reference Faber-Elmann A, Sthoeger Z, Tcherniack A, Dayan M, Mozes E (2002) Activity of matrix metalloproteinase-9 is elevated in sera of patients with systemic lupus erythematosus. Clin Exp Immunol 127:393–398CrossRefPubMedPubMedCentral Faber-Elmann A, Sthoeger Z, Tcherniack A, Dayan M, Mozes E (2002) Activity of matrix metalloproteinase-9 is elevated in sera of patients with systemic lupus erythematosus. Clin Exp Immunol 127:393–398CrossRefPubMedPubMedCentral
11.
go back to reference Galis ZS, Khatri JJ (2002) Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 90:251–262PubMed Galis ZS, Khatri JJ (2002) Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 90:251–262PubMed
14.
go back to reference Hardy CJ, Palmer BP, Muir KR, Sutton AJ, Powell RJ (1998) Smoking history, alcohol consumption, and systemic lupus erythematosus: a case-control study. Ann Rheum Dis 57:451–455CrossRefPubMedPubMedCentral Hardy CJ, Palmer BP, Muir KR, Sutton AJ, Powell RJ (1998) Smoking history, alcohol consumption, and systemic lupus erythematosus: a case-control study. Ann Rheum Dis 57:451–455CrossRefPubMedPubMedCentral
15.
go back to reference Heussen C, Dowdle EB (1980) Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates. Anal Biochem 102:196–202CrossRefPubMed Heussen C, Dowdle EB (1980) Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates. Anal Biochem 102:196–202CrossRefPubMed
19.
go back to reference Matache C, Stefanescu M, Dragomir C, Tanaseanu S, Onu A, Ofiteru A, Szegli G (2003) Matrix metalloproteinase-9 and its natural inhibitor TIMP-1 expressed or secreted by peripheral blood mononuclear cells from patients with systemic lupus erythematosus. J Autoimmun 20:323–331CrossRefPubMed Matache C, Stefanescu M, Dragomir C, Tanaseanu S, Onu A, Ofiteru A, Szegli G (2003) Matrix metalloproteinase-9 and its natural inhibitor TIMP-1 expressed or secreted by peripheral blood mononuclear cells from patients with systemic lupus erythematosus. J Autoimmun 20:323–331CrossRefPubMed
21.
24.
go back to reference Ribbens C, Martin y Porras M, Franchimont N, Kaiser MJ, Jaspar JM, Damas P, Houssiau FA, Malaise MG (2002) Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment. Ann Rheum Dis 61:161–166CrossRefPubMedPubMedCentral Ribbens C, Martin y Porras M, Franchimont N, Kaiser MJ, Jaspar JM, Damas P, Houssiau FA, Malaise MG (2002) Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment. Ann Rheum Dis 61:161–166CrossRefPubMedPubMedCentral
25.
go back to reference Robak E, Wierzbowska A, Chmiela M, Kulczycka L, Sysa-Jedrejowska A, Robak T (2006) Circulating total and active metalloproteinase-9 and tissue inhibitor of metalloproteinases-1 in patients with systemic lupus erythomatosus. Mediat Inflamm 2006:17898. https://doi.org/10.1155/MI/2006/17898 Robak E, Wierzbowska A, Chmiela M, Kulczycka L, Sysa-Jedrejowska A, Robak T (2006) Circulating total and active metalloproteinase-9 and tissue inhibitor of metalloproteinases-1 in patients with systemic lupus erythomatosus. Mediat Inflamm 2006:17898. https://​doi.​org/​10.​1155/​MI/​2006/​17898
Metadata
Title
Matrix metalloproteinase-2 and -9 activity levels increase in cutaneous lupus erythematosus lesions and correlate with disease severity
Authors
Goksen Ertugrul
Didem Keles
Gulgun Oktay
Sebnem Aktan
Publication date
01-03-2018
Publisher
Springer Berlin Heidelberg
Published in
Archives of Dermatological Research / Issue 2/2018
Print ISSN: 0340-3696
Electronic ISSN: 1432-069X
DOI
https://doi.org/10.1007/s00403-018-1811-2

Other articles of this Issue 2/2018

Archives of Dermatological Research 2/2018 Go to the issue